Vimal Mehta, CEO, President, Secretary at BioXcel Therapeutics, Inc. (BTAI), bought 2,000 shares at $4.27 ($9K) on 2018-12-14, disclosed to the SEC on 2018-12-14.
Open-market purchase of $9k BTAI by CEO, President, Secretary. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.27 | 800 | $3K | 39.0% |
| 2 | $4.32 | 200 | $864 | 9.9% |
| 3 | $4.48 | 500 | $2K | 25.6% |
| 4 | $4.49 | 400 | $2K | 20.5% |
| 5 | $4.50 | 100 | $450 | 5.1% |
| Total | $4.38 avg | 2,000 |
| $9K |
| 100% |
| Filing → |
| BTAI | SELL | 2024-09-17 | $1K | — | Filing → |
| BTAI | SELL | 2024-06-18 | $3K | — | Filing → |
| BTAI | SELL | 2024-04-08 | $14K | — | Filing → |